Filing Analysis
Passage Bio, Inc. has entered into a definitive merger agreement to acquire Remix Therapeutics, Inc. via a reverse merger structure. The transaction includes a concurrent $100 million financing and will result in the combined company being led by Remix's current CEO.
🚩 Red Flags
- Significant dilution expected due to the massive disparity in equity valuations ($20M vs $226M) and the concurrent $100M financing.
- The transaction effectively functions as a reverse takeover, where the smaller company (Passage Bio) is being absorbed by the larger entity (Remix).
- High termination fee for Remix ($17.5M) compared to Passage Bio ($1.548M) suggests significant leverage in favor of the acquirer/surviving entity.
📋 Key Facts
- Passage Bio (PASG) to merge with Remix Therapeutics, Inc.
- Remix is ascribed an aggregate equity value of $226 million; Passage Bio's equity value is expected to be approximately $20 million (subject to net cash adjustments).
- A concurrent financing will raise at least $100 million in gross proceeds via common stock and convertible notes prior to the merger.
- The combined company's Board of Directors will consist of nine members, all designated by Remix.
- Peter Smith, Ph.D., current CEO of Remix, will become the CEO of the combined company.
- Termination fee for Passage Bio if it enters an alternative transaction is $1.548 million; termination fee for Remix if it enters a superior offer is $17.5 million.
Passage Bio terminated two material agreements: a research and license collaboration with Gemma Biotherapeutics for CNS indications (including Huntington's disease) and a long-term office lease in Philadelphia.
🚩 Red Flags
- Simultaneous termination of a key R&D partner (Gemma) and a physical headquarters (moving to remote-only status).
- Significant cash outlay of $2.3 million for a lease termination fee, which is highly material for a micro-cap biotech company.
- Termination of R&D programs (Huntington's and TLE) may indicate a strategic pivot or lack of funding.
📋 Key Facts
- Terminated Research, Collaboration and License Agreement with Gemma Biotherapeutics, Inc. dated July 31, 2024.
- Gemma had been conducting preclinical and IND-enabling work for Huntington's disease and Temporal Lobe Epilepsy programs.
- Entered into a lease termination agreement on May 22, 2026, for 37,000 square feet of office space at 2005 Market Street, Philadelphia.
- The lease was originally set to expire in December 2031.
- The company paid a termination fee of $2.3 million to the landlord.
Passage Bio, Inc. reported the voting results from its 2026 Annual Meeting of Stockholders held on May 19, 2026. Stockholders elected two Class III directors, ratified the appointment of KPMG LLP as the independent auditor, and approved executive compensation and an annual frequency for future compensation votes.
📋 Key Facts
- The Annual Meeting of Stockholders was held on May 19, 2026.
- Athena Countouriotis, M.D. and Sandip Kapadia were elected as Class III directors to serve until the 2029 Annual Meeting.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 2,083,031 votes 'For'.
- Stockholders approved, on an advisory basis, the compensation of named executive officers and voted in favor of holding future advisory votes on executive compensation every year.
Passage Bio, Inc. announced a massive 75% workforce reduction as part of a formal review of strategic alternatives. The company expects to incur approximately $3.3 million in severance and exit costs through the third quarter of 2026.
🚩 Red Flags
- Extreme workforce reduction (75%) indicates a potential cessation of primary R&D activities.
- The 'review of strategic alternatives' language often precedes a company sale, merger, or liquidation.
- Significant cash charge of $3.3 million for severance may further strain liquidity.
📋 Key Facts
- Announced a 75% reduction in workforce on April 28, 2026.
- Estimated aggregate severance and exit costs of approximately $3.3 million.
- Restructuring is part of a previously announced effort to review strategic alternatives to maximize shareholder value.
- The plan is expected to be substantially complete by the end of the third quarter of 2026.
- Severance benefits are contingent upon employees signing a general release of claims.
Passage Bio announced positive interim Phase 1/2 data for PBFT02 but disclosed that the FDA requires a randomized controlled registrational trial, which the company cited as a significant financial and logistical challenge. As a result, the company has initiated a formal review of strategic alternatives, including a potential merger, sale, or asset disposition, and has engaged Wedbush PacGrow as a financial advisor.
🚩 Red Flags
- FDA mandate for a randomized controlled trial creates a major regulatory and financial hurdle that the company admits it may not be able to meet independently.
- The initiation of a strategic review often indicates the company is running low on cash or lacks the resources to advance its lead programs.
- Previous serious adverse events (SAEs) include venous sinus thrombosis and hepatotoxicity in Dose 1 patients.
📋 Key Facts
- PBFT02-treated patients showed a 64% reduction in whole brain atrophy and a 54% reduction in frontotemporal cortex atrophy at 12 months compared to natural history data.
- CSF progranulin (PGRN) expression increased from <3 ng/mL at baseline to a mean of 22.8 ng/mL at 12 months.
- The FDA indicated that a randomized controlled registrational study design is required for PBFT02 in FTD-GRN.
- The company has initiated a strategic review process to evaluate mergers, acquisitions, reverse mergers, or asset sales.
- Wedbush PacGrow has been engaged as the financial advisor for the strategic review.
Passage Bio terminated its 15-year lease for a 62,000 square foot laboratory facility in Hopewell, paying a $4.8 million termination fee. The move follows a January 2025 restructuring and aims to eliminate long-term liabilities for a facility the company no longer uses.
🚩 Red Flags
- Substantial $4.8 million cash outflow for a termination fee.
- Reference to a prior restructuring in January 2025 indicating past financial or operational distress.
- Cautionary language regarding the potential for capital resources to be depleted sooner than expected.
📋 Key Facts
- Entered into a lease termination agreement with Hopewell Campus Owner LLC on March 4, 2026.
- Agreed to pay a termination fee of approximately $4.8 million plus accrued rent through February 14, 2026.
- The original lease was for 62,000 square feet and had a 15-year term that commenced in March 2021.
- Operations at the facility had already ceased in January 2025 following a corporate restructuring.
- Company estimates current cash and cash equivalents will fund operations through the first quarter of 2027.
Passage Bio, Inc. announced its financial results for the fiscal year ended December 31, 2025, and issued an updated corporate presentation. This filing serves as a routine disclosure of annual performance and strategic updates for investors.
📋 Key Facts
- Reported financial results for the fiscal year ended December 31, 2025, on March 3, 2026.
- Released an updated corporate presentation as part of Regulation FD disclosure.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
- The report was signed by Kathleen Borthwick, Chief Financial Officer.
Passage Bio, Inc. updated its corporate presentation and provided preliminary cash position details as of December 31, 2025. The company reports approximately $46 million in cash, cash equivalents, and marketable securities.
🚩 Red Flags
- Limited cash runway: The company expects funds to last only until Q1 2027, indicating a potential need for capital raising within the next 12-15 months.
- Preliminary/Unaudited data: Financial figures are subject to change upon completion of year-end audits.
📋 Key Facts
- Preliminary cash, cash equivalents, and marketable securities: ~$46 million (as of Dec 31, 2025).
- Cash runway expected to extend into the first quarter of 2027.
- The reported figures are preliminary, unaudited, and subject to final audit adjustments.
Passage Bio, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025, and provided an updated corporate presentation.
📋 Key Facts
- Announced financial results for the quarter ended September 30, 2025.
- Released an updated corporate presentation (Exhibit 99.2).
- The company is classified as an 'emerging growth company'.
- Filing date: November 10, 2025.
Saqib Islam has resigned from the Board of Directors and the Audit Committee of Passage Bio, Inc., effective September 16, 2025. The company appointed Dr. Athena Countouriotis to the Audit Committee to fill the vacancy.
🚩 Red Flags
- None identified; the filing explicitly states the resignation was not due to any disagreement regarding operations, policies, or practices.
📋 Key Facts
- Saqib Islam resigned from the Board of Directors and the Audit Committee on September 16, 2025.
- The resignation was effective immediately.
- Dr. Athena Countouriotis, M.D., has been appointed to the Audit Committee to fill the vacancy.
- The Board size was reduced from eight members to seven members.
Passage Bio, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2025, and provided an updated corporate presentation.
📋 Key Facts
- Report date: August 12, 2025
- Announced financial results for the quarter ended June 30, 2025 (Item 2.02)
- Updated its corporate presentation (Item 7.01)
- Company is classified as an emerging growth company
Passage Bio, Inc. has regained compliance with Nasdaq's minimum bid price requirement (Rule 5450(a)(1)). The company successfully maintained a closing bid price of at least $1.00 for 10 consecutive business days as of July 28, 2025.
🚩 Red Flags
- Historical context of delisting risk (the reason for this filing was a prior failure to meet minimum bid requirements).
📋 Key Facts
- The Company regained compliance with Nasdaq Listing Rule 5450(a)(1) on July 28, 2025.
- Compliance was achieved by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days.
- Nasdaq has officially closed the listing matter regarding the minimum bid price deficiency.
- The company previously fell below compliance on August 1, 2024.
Passage Bio, Inc. is implementing a 1-for-20 reverse stock split effective July 14, 2025. This action reduces the total outstanding shares from approximately 62.4 million to 3.12 million.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing requirements or combat low share price)
- Significant reduction in share count/liquidity profile
📋 Key Facts
- Reverse stock split ratio: 1-for-20
- Effective date/time: July 14, 2025, at 12:01 am ET
- Pre-split shares outstanding: ~62,405,898
- Post-split shares outstanding: ~3,120,295
- New CUSIP number: 702712 209
- Fractional shares will be rounded up to the nearest whole share.
Passage Bio, Inc. provided updated interim clinical data for its PBFT02 program in treating frontotemporal dementia (FTD-GRN). While biomarker data shows significant increases in progranulin expression and a reduction in NfL neurofilament levels, the company reported several serious adverse events (SAEs), including venous sinus thrombosis and pulmonary embolism.
🚩 Red Flags
- Serious Adverse Events (SAEs) reported, including pulmonary embolism which was assessed as 'possibly related to treatment'.
- Clinical protocol amendment required to introduce prophylactic anticoagulation due to safety signals.
- Safety monitoring is being increased for subsequent patients in the trial.
📋 Key Facts
- PBFT02 Dose 1 resulted in mean CSF PGRN increase from <3 ng/mL to 25.9 ng/mL at 12 months post-treatment.
- Plasma NfL levels increased by only 4% on average at 12 months, compared to an expected 28-29% annual increase in untreated patients.
- Reported three serious adverse events (SAEs) in three of eight patients: venous sinus thrombosis (n=2), hepatotoxicity, and pulmonary embolism.
- The company is amending the upliFT-D clinical trial protocol to include a short course of low-dose prophylactic anticoagulation due to safety concerns.
- Anticipated milestones include submitting the protocol amendment in July 2025 and seeking regulatory feedback on registrational trial design in H1 2026.
Passage Bio, Inc. held its 2025 Annual Meeting of Stockholders on May 28, 2025, where stockholders approved a proposal to authorize the Board to implement a reverse stock split between 1-for-5 and 1-for-50 prior to year-end.
🚩 Red Flags
- Approval of a reverse stock split (ratio up to 1-for-50) is often used to regain compliance with minimum bid price requirements on exchanges like Nasdaq.
- The wide range of the potential split ratio (up to 1-for-50) suggests significant uncertainty regarding the current share price or regulatory standing.
📋 Key Facts
- Annual Meeting held on May 28, 2025.
- Stockholders approved a reverse stock split ratio between 1-for-5 and 1-for-50, to be determined by the Board before December 31, 2025.
- Two Class II directors (Maxine Gowen, Ph.D. and Dolan Sondhi, Ph.D.) were elected to three-year terms expiring in 2028.
- Ratification of KPMG LLP as independent auditor for fiscal year ending Dec 31, 2025 was approved.
Passage Bio, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025, and provided an updated corporate presentation.
📋 Key Facts
- Announced quarterly financial results for the period ending March 31, 2025.
- Released an updated corporate presentation to provide current company information.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
Passage Bio, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024, and provided an updated corporate presentation.
📋 Key Facts
- Reported date: March 4, 2025
- Financial results released for the year ended December 31, 2024 (Exhibit 99.1)
- Updated corporate presentation provided (Exhibit 99.2)
Passage Bio, Inc. has successfully transferred its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market due to failure to meet minimum bid price requirements. This transfer grants the company an additional 180-day grace period until July 28, 2025, to regain compliance by achieving a $1.00 closing bid price.
🚩 Red Flags
- Delisting risk: The company is currently non-compliant with Nasdaq's minimum bid price requirement.
- Potential for Reverse Stock Split: Management has signaled that a reverse split may be necessary to boost share price, which often results in significant dilution and negative market sentiment.
- Downgrade in listing tier: Moving from Global Select to Capital Market indicates a perceived reduction in liquidity or market profile.
📋 Key Facts
- Nasdaq approved the transfer from Global Select Market to Capital Market effective January 30, 2025.
- The company failed to meet the minimum $1.00 bid price requirement during its initial 180-day period ending Jan 28, 2025.
- A new 180-day compliance period has been granted, expiring July 28, 2025.
- To regain compliance, the stock must close at or above $1.00 for at least 10 consecutive business days before the deadline.
- The company explicitly mentioned considering a reverse stock split as a potential method to cure the deficiency.
Passage Bio is undergoing a significant restructuring plan involving a 55% workforce reduction and the closure of its New Jersey laboratory operations. While the company reports a strong cash runway into Q1 2027, the simultaneous announcement of material impairments and large-scale layoffs indicates a strategic pivot or cost-cutting necessity.
🚩 Red Flags
- Significant workforce reduction (55%) often indicates financial distress or a pivot in business model.
- Material impairment expected on laboratory equipment and right-of-use assets.
- Closure of major physical laboratory facilities.
📋 Key Facts
- Workforce reduction of approximately 55% to align with R&D strategy.
- Ceasing lab operations at ~62,000 sq. ft. facility in Hopewell, NJ.
- Expected annual operating cost savings of $9.0 million to $11.0 million.
- Estimated one-time restructuring/severance costs of ~$2.0 million in Q1 2025.
- Anticipated impairment charges for laboratory equipment between $1.0 million and $3.0 million in Q1 2025.
- Cash, cash equivalents, and marketable securities position as of Dec 31, 2024, is ~$76.8 million.
- Projected cash runway extends into the first quarter of 2027.
Passage Bio, Inc. announced its financial results for the quarter ended September 30, 2024 and updated its corporate presentation.
📋 Key Facts
- Reported quarterly financial results for the period ending September 30, 2024.
- Updated the company's corporate presentation as of November 13, 2024.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
Passage Bio, Inc. provided a scientific presentation at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress on October 24, 2024. The filing serves to disclose information via Regulation FD through a press release and a scientific presentation.
📋 Key Facts
- Company presented scientific data at the ESGCT 31st Annual Congress.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure).
- Information is provided in Exhibits 99.1 (press release) and 99.2 (presentation).
Passage Bio, Inc. issued a press release and updated its corporate presentation regarding interim safety and biomarker data from its Phase 1/2 clinical trial of PBFT02 for frontotemporal dementia.
🚩 Red Flags
- No significant red flags identified; clinical data is presented as positive biomarker updates.
📋 Key Facts
- Announced updated interim safety and biomarker data for Cohort 1 patients in the upliFT-D Phase 1/2 trial as of August 20, 2024.
- PBFT02 was well-tolerated in all patients (patients 2, 3, 4, and 5) following an enhanced immunosuppression regimen.
- Observed increased progranulin (PGRN) levels in cerebrospinal fluid (CSF) in all patients relative to baseline.
- Reported up to a 6-fold increase in CSF PGRN at one month and up to a 10-fold increase at six months.
- CSF PGRN levels exceeded the range found in healthy adult controls (3.3 to 8.2 ng/mL).
- Plasma PGRN expression remained below healthy reference levels across all patients.
Passage Bio, Inc. announced the appointment of Thomas Kassberg to its Board of Directors and Audit Committee, effective September 10, 2024.
📋 Key Facts
- Thomas Kassberg appointed as Class I director and member of the Audit Committee.
- Effective date of appointment: September 10, 2024.
- Mr. Kassberg currently serves as Chief Business Officer and EVP at Ultragenyx Pharmaceutical Inc.
- Compensation includes cash compensation and non-incentive stock options with a grant date fair value of $90,000.
- Options vest in equal monthly installments over a three-year period starting September 30, 2024.
Passage Bio, Inc. announced a material impairment charge and a sublease agreement for its laboratory space in New Jersey. The company expects to recognize non-cash impairment expenses between $3.5 million and $5.5 million due to organizational redesign and asset outlicensing.
🚩 Red Flags
- Material impairment charge ($3.5M-$5.5M) indicates significant write-downs of long-lived assets, leasehold improvements, and equipment.
- The impairments are driven by 'organizational redesign' and the outlicensing of key drug candidates (PBGM01, PBKR03, PBML04), suggesting a contraction in core operations.
📋 Key Facts
- Company entered into a sublease agreement for ~3,200 sq. ft. (5% of total leased space) in Hopewell, NJ.
- Sublease term runs from September 2024 through September 2029, with an option to extend to December 2032.
- Base sublease rent is $0.1 million per year, increasing by 2.5% annually.
- Expected non-cash impairment charge of $3.5 million to $5.5 million for the period ending September 30, 2024.
- The company expects the sublease to reduce annualized net loss by approximately $0.1 to $0.2 million compared to 2023 levels.
Passage Bio, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2024 and provided an updated corporate presentation.
📋 Key Facts
- Reported financial results for the quarter ended June 30, 2024 via press release (Exhibit 99.1).
- Released an updated corporate presentation (Exhibit 99.2) on August 8, 2024.
- The company is classified as an emerging growth company.
Passage Bio, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement after its stock closed below $1.00 for 30 consecutive business days. The company has an initial 180-day period to regain compliance by January 28, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price requirement ($1.00)
- Requirement of a potential reverse stock split to meet compliance standards in the future
📋 Key Facts
- Received notice from Nasdaq Listing Qualifications staff on August 1, 2024.
- Non-compliance due to closing bid price falling below $1.00 for 30 consecutive business days (Nasdaq Rule 5450(a)(1)).
- Initial compliance period granted until January 28, 2025.
- To regain compliance, stock must close at or above $1.00 for at least 10 consecutive business days before the deadline.
- Potential for an additional 180-day grace period to transfer to Nasdaq Capital Market if certain conditions are met.
Passage Bio has entered into a series of significant sublicense and collaboration agreements with Gemma Biotherapeutics, involving the outlicensing of three programs (PBGM01, PBKR03, and PBML04) for up to $124 million in potential milestone payments. The company is simultaneously undergoing a strategic pivot and leadership transition, including the resignation of its Chief Medical Officer.
🚩 Red Flags
- Departure of Chief Medical Officer (CMO) Mark Forman, M.D., Ph.D.
- Related-party transaction: Gemma Biotherapeutics was co-founded by a current Company consultant (Dr. James Wilson).
- Strategic pivot: The company is shifting focus toward 'elevated progranulin' in neurodegenerative disorders, indicating a change in core research direction.
📋 Key Facts
- Entered into 'Gemma Sublicenses' with Gemma Biotherapeutics, Inc. on July 31, 2024.
- Sublicense terms include $10M initial payment for clinical product supply and up to $114M in development/commercial milestones.
- Passage Bio will receive single-digit royalties on worldwide net sales of the outlicensed programs.
- Gemma Biotherapeutics is co-founded by Dr. James Wilson, a current Scientific Advisor to Passage Bio.
- The company's cash position as of June 30, 2024, was approximately $91.8 million.
- Management expects current cash plus Gemma payments to fund operations through Q2 2026.
- Chief Medical Officer Mark Forman, M.D., Ph.D., is resigning effective August 2, 2024.
- Appointed Susan Browne, Ph.D. as CSO and Stuart Henderson as CBO, effective August 1, 2024.
Passage Bio, Inc. announced positive feedback from the FDA during a Type C meeting regarding its proposal to evaluate PBFT02 for treating frontotemporal dementia (FTD) patients with C9orf72 mutations. The company plans to amend its ongoing Phase 1/2 study and initiate dosing for this specific patient population in the first half of 2025.
📋 Key Facts
- Received positive feedback from the FDA during a Type C meeting regarding PBFT02 for FTD-C9orf72 patients.
- Company intends to amend the protocol for the ongoing upliFT-D Phase 1/2 global study (currently focused on FTD-GRN) to include the new C9orf72 population.
- Planned timeline for initiating dosing of FTD-C9orf72 patients is the first half of 2025.
Passage Bio, Inc. held its 2024 Annual Meeting of Stockholders on May 21, 2024. The meeting resulted in the election of two Class I directors and the ratification of KPMG LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting of Stockholders held on May 21, 2024.
- Election of William Chou, M.D. to a three-year term (expires 2027).
- Election of Derrell Porter, M.D. to a three-year term (expires 2027).
- Ratification of KPMG LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024.
Passage Bio, Inc. announced its quarterly financial results for the period ended March 31, 2024, and updated its corporate presentation.
📋 Key Facts
- Reported financial results for the quarter ended March 31, 2024 via press release (Exhibit 99.1).
- Updated corporate presentation released on May 14, 2024 (Exhibit 99.2).
- Company is classified as an emerging growth company.
Passage Bio, Inc. announced the appointment of Kathleen Borthwick as Chief Financial Officer, effective March 1, 2024. The company also released its full-year 2023 financial results and updated its corporate presentation.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Kathleen Borthwick appointed CFO effective March 1, 2024; she previously served as Interim CFO since July 2023.
- Borthwick's compensation includes a base salary of $422,240 and an annual bonus target of up to 40%.
- Equity grant: 227,000 stock options with a 48-month vesting schedule starting one month after the effective date.
- Company released FY 2023 financial results via press release on March 4, 2024.
- Updated corporate presentation issued under Regulation FD.
Passage Bio, Inc. has regained compliance with Nasdaq's minimum bid price requirement (Rule 5450(a)(1)). The company successfully maintained a closing bid price of at least $1.00 per share for 10 consecutive business days as of February 28, 2024.
🚩 Red Flags
- Historical delisting risk (stock price was below $1.00 for a significant period).
📋 Key Facts
- The Company regained compliance with Nasdaq Listing Rule 5450(a)(1) on February 29, 2024.
- Compliance was achieved by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days ending February 28, 2024.
- The Nasdaq listing matter is officially considered closed.
- The company previously fell out of compliance on August 31, 2023, due to the stock trading below $1.00 for 30 consecutive business days.
Passage Bio, Inc. updated its corporate presentation via a Regulation FD disclosure on January 5, 2024.
📋 Key Facts
- The company updated its corporate presentation (Exhibit 99.1).
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- Kathleen Borthwick signed as Interim Chief Financial Officer.